#USA #New York #Rosen Law Firm #Securities Class Action #Aardvark Therapeutics

AARDVARK THERAPEUTICS SECURITIES CLASS ACTION

In a crucial update for investors, Rosen Law Firm, a prominent global law firm specializing in investor rights, has reminded shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD) about the class action lawsuit concerning their stock transactions. This reminder comes ahead of the pressing deadline of October 13, 2026, when investors impacted by potential financial losses exceeding $100,000 must secure legal representation to be eligible to act as lead plaintiffs in the case.

Overview of the Class Action

The securities class action pertains to Aardvark's initial public offering (IPO) that took place on February 13, 2025, and encompasses purchases of Aardvark securities from that date until May 14, 2026. Investors who acquired stocks through the registration statement related to this IPO may qualify for compensation without any upfront costs, under a contingency fee basis.

Deadlines and Participation

To participate in the Aardvark class action, investors are encouraged to visit Rosen Law Firm’s official site or to contact attorney Phillip Kim via the firm’s toll-free number at 866-767-3653. The firm has already initiated legal proceedings, and all potential lead plaintiffs must file their motions by the impending deadline.

Why Choose Rosen Law Firm?

Rosen Law Firm stands out due to its remarkable track record in managing securities class actions globally. The firm emphasizes the importance of selecting experienced legal counsel with proven success in successfully representing investors. Unlike many firms that may lack depth in securities law, Rosen Law has achieved significant settlements, including the largest securities class action settlement against a Chinese company and recognition as a top-ranking law firm in terms of settlement success over multiple years.

Allegations Against Aardvark Therapeutics

According to the class action lawsuit, Aardvark Therapeutics and its representatives are accused of disseminating materially false or misleading information about the company’s operational integrity and business outlook. Crucial allegations include failure to inform investors regarding the safety and efficacy profile of their product, ARD-101, which was reportedly overstated in terms of its clinical, regulatory, and commercial prospects.

When true information surfaced regarding these discrepancies, it led to substantial financial losses for investors. The lawsuit argues that defendants' statements were misleading throughout the class period, causing harm to shareholders who believed in the positive outlook touted by company executives.

What Investors Should Do Now

Investors who have suffered losses from their investments in Aardvark Therapeutics should not delay in taking action. Even if a class has not yet been certified by the court, affected individuals have the option to remain passive participants or actively associate with counsel to seek recovery. The outcome of potential future recoveries does not hinge on being the lead plaintiff, although taking initiative by securing representation can enhance chances of a favorable result.

For additional information and updates on the case, interested parties are encouraged to visit Rosen Law Firm’s social media channels on LinkedIn, Twitter, or Facebook.

Contact Information

Participants can reach the firm directly through the following:

• - Laurence Rosen, Esq.
• - Phillip Kim, Esq.
• - The Rosen Law Firm, P.A.
• - 275 Madison Avenue, 40th Floor, New York, NY 10016
• - Tel: (212) 686-1060
• - Toll-Free: (866) 767-3653
• - Email: [email protected]
• - Website: rosenlegal.com

Mood your decisions wisely; the clock is ticking, and timely action is crucial for those impacted by Aardvark Therapeutics. Don’t miss the chance to seek the justice and financial recovery you deserve.